Benzinga · Feb 2, 2026
PB
NASDAQ · PBMWW
Psyence Biomedical Ltd. Warrant
Healthcare · Biotechnology
$0.02
Down-$0.00 (-8.48%)
Updated Oct 9, 2026, 1:10 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.72K
- P/E ratio
- -0.19
- Dividend yield
- 0.00%
- 52-week range
- $0.02 – $0.09
- Volume
- 18.86K
- Avg. volume
- 59.67K
Price performance · PBMWW
PBMWW price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
PBMWW closed at $0.02 after 20 trading sessions, down 46.64% for the selected period.
- Last close
- $0.02
- Period change
- -46.64%
- Period low
- $0.02
- Period high
- $0.03
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $0.0165 | $0.0165 | $0.0151 | $0.0151 | 18.86K |
| Oct 7, 2026 | $0.0191 | $0.0191 | $0.0165 | $0.0165 | 51.28K |
| Oct 6, 2026 | $0.021 | $0.0219 | $0.0195 | $0.0195 | 26.37K |
| Oct 5, 2026 | $0.0197 | $0.021 | $0.0197 | $0.021 | 40.83K |
| Oct 1, 2026 | $0.0207 | $0.0225 | $0.0207 | $0.0211 | 240.06K |
| Sep 30, 2026 | $0.021 | $0.021 | $0.021 | $0.021 | 12.46K |
| Sep 29, 2026 | $0.022 | $0.0227 | $0.0198 | $0.022 | 408.22K |
| Sep 28, 2026 | $0.0237 | $0.0237 | $0.0237 | $0.0237 | 279.59 |
| Sep 25, 2026 | $0.0231 | $0.033 | $0.0231 | $0.0296 | 31.81K |
| Sep 24, 2026 | $0.0227 | $0.0231 | $0.0227 | $0.0231 | 4.44K |
| Sep 23, 2026 | $0.0257 | $0.0342 | $0.0257 | $0.0342 | 14.6K |
| Sep 22, 2026 | $0.0228 | $0.0349 | $0.0227 | $0.0288 | 16.84K |
| Sep 21, 2026 | $0.0227 | $0.0228 | $0.0227 | $0.0228 | 10.44K |
| Sep 18, 2026 | $0.0251 | $0.0251 | $0.0251 | $0.0251 | 148.73 |
| Sep 17, 2026 | $0.0348 | $0.039 | $0.0226 | $0.0226 | 3.1K |
| Sep 16, 2026 | $0.0286 | $0.0286 | $0.0286 | $0.0286 | 1K |
| Sep 15, 2026 | $0.03 | $0.03 | $0.0287 | $0.0287 | 15.88K |
| Sep 14, 2026 | $0.03 | $0.0349 | $0.0299 | $0.0349 | 26.37K |
| Sep 11, 2026 | $0.03 | $0.03 | $0.0202 | $0.0289 | 27.69K |
| Sep 10, 2026 | $0.0219 | $0.0283 | $0.0219 | $0.0283 | 18.94K |
Latest PBMWW news
The latest Smart Investors Daily articles mentioning PBMWW.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PBMWW research
Overview
Company profile and research snapshot.
Company profile
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Jan 30, 2026
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Yahoo · Nov 12, 2025
Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Psyence BioMed (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that, through its strategic investment in PsyLabs, it is now the only publicly listed psychedelics company with active operations and manufacturing capabilities based in Africa – the natural and original source of ibogaine. Derived from the Tabernanthe ibo
GlobeNewswire Inc. · Nov 3, 2025
Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
Psyence BioMed made a $3.5 million follow-on investment in PsyLabs, a leading producer of psychedelic pharmaceutical ingredients, to secure a sustainable and ethical supply chain for its clinical research programs in mental health therapies.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
